Lunelle monthly injectable contraceptive. An effective, safe, and convenient new birth control option

Arch Gynecol Obstet. 2001 Aug;265(3):119-23. doi: 10.1007/s004040100174.

Abstract

Lunelle, an injectable estrogen/progestin contraceptive, is administered on a monthly basis and is now available as the first monthly injectable in the United States. International and US clinical trials have established its safety and confirmed its contraceptive efficacy. Fertility returns rapidly after discontinuation of injections. Studies have noted a high level of patient satisfaction with Lunelle, suggesting that monthly injectable contraception will become a first-line contraceptive option in the United States.

Publication types

  • Review

MeSH terms

  • Contraception
  • Contraceptive Agents, Female / administration & dosage*
  • Contraceptive Agents, Female / adverse effects
  • Drug Administration Schedule
  • Estradiol / administration & dosage*
  • Estradiol / analogs & derivatives*
  • Female
  • Fertility / drug effects
  • Humans
  • Injections, Intramuscular
  • Medroxyprogesterone Acetate / administration & dosage*
  • Medroxyprogesterone Acetate / adverse effects
  • Patient Satisfaction
  • Pregnancy
  • Progesterone / blood
  • Time Factors
  • Treatment Outcome
  • Uterine Hemorrhage

Substances

  • Contraceptive Agents, Female
  • Lunelle
  • Progesterone
  • Estradiol
  • Medroxyprogesterone Acetate